Leadership and Members


Meet the leaders and members of the Leukemia Research program at the OSUCCC – James who work to develop targeted therapies for leukemia.

Leaders

John Byrd, MD

Dr. Byrd’s research accomplishments relate best to studies done between the laboratory and clinic (translational work) with several different therapeutic agents active in chronic lymphocytic leukemia (CLL) and related leukemias and lymphomas. His work has shown that therapeutic agents such as.

Read More

Ramiro Garzon, MD

My laboratory is interested in discovering the role of non-coding RNAs in normal Blood formation and how these RNAs may cooperate with other protein coding genes during leukemogenesis

Read More

Members

Lynne Abruzzo, MD, PhD

Lynne Abruzzo, MD, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where she centers her research on low-grade B-cell leukemia and lymphoma, including chronic lymphocytic leukemia (CLL). She is a co-holder of 17 patents in the United States and other countries for breast.

Read More

Lapo Alinari, MD, PhD

Lapo Alinari, MD, PhD, is an Assistant Professor of Internal Medicine in the Division of Hematology and a member of the Leukemia Research Program at the OSUCCC – James. Dr. Alinari’s research focuses on the identification of novel targets and preclinical as well as clinical development of.

Read More

Leslie Andritsos, MD

Leslie Andritsos, MD, is a member of the Leukemia Research Program at the OSUCCC – James, where she focuses her research on chronic lymphocytic leukemia (CLL) and bone marrow transplants. She also she serves as principal or co-principal investigator for several research projects.

Read More

Jeffrey Auletta, MD

Dr. Jeffery Auletta Jeffery Auletta, MD, is a member of the Leukemia Research Program at the OSUCCC – James. Dr. Auletta is the Director of the Pediatric Blood and Marrow Transplant Program at Nationwide Children’s Hospital, which works closely with the OSUCCC – James Cell Therapy Lab and Adult.

Read More

Farrukh Awan, MD

Farrukh Tauseef Awan, MD, MS, is a member of the Leukemia Research Program at the OSUCCC – James, where he is a medical oncologist who treats patients with leukemia and other blood cancers. He has specific expertise in chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL) and non-Hodgkin.

Read More

Robert Baiocchi, MD, PhD

Robert Baiocchi, MD, PhD, is a member of the Leukemia Research Program at the OSUCCC – James. His work has led to 11 patents and pending patents, including one for methods to treat viral-associated lymphoproliferative disorders with TGF-ß antagonists, one for compositions and methods relating to.

Read More

Sharyn Baker, PharmD, PhD

Dr. Baker’s cancer-relevant research interests broadly cover translational and clinical pharmacology of anti-cancer agents. Recently, her laboratory has focused on the preclinical development of anti-cancer agents for the treatment of acute myeloid leukemia (AML), with an emphasis on tyrosine.

Read More

Bhavana Bhatnagar, DO

My primary clinical interest is acute myeloid leukemia (AML) and my research interests pertain to : 1 -The development and application of novel therapies in early phase clinical trials that are both effective and well-tolerated for the treatment of poor-risk AML, particularly in the

Read More

James Blachly, MD

Dr. Blachly's interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics; namely, whether and how mutations and transcriptional attributes (including gene expression level, but also alternative splicing, alternative polyadenylation, non-protein coding

Read More

Clara Bloomfield, MD

After serving as director of the OSU Comprehensive Cancer Center from 1997 to July 2003, Dr. Bloomfield became Senior Advisor to the OSU cancer program and the charter member of the OSU Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of

Read More

Jon Butchar, PhD

As a member of the Leukemia Research Program at the OSUCCC – James, Jonathan Butchar, PhD, seeks to improve the efficacy of antibody therapy through his research. His work brings together pathogenesis and tumor immunotherapy by studying interactions between Fc-gamma receptor and Toll-like.

Read More

Michael Caligiuri, MD

Michael A. Caligiuri, MD, is director of The Ohio State University Comprehensive Cancer Center, chief executive officer of Ohio State’s James Cancer Hospital and Solove Research Institute, and holder of the John L.

Read More

Carlos Castro, PhD

Carlos Castro, PhD, brings an engineering perspective as a member of the Leukemia Research Program at the OSUCCC – James. He seeks to use engineering approaches with nanotechnology and biophysics experimental tools to characterize and model physical properties and behaviors of complex.

Read More

Beth Christian, MD

Dr. Christian's research interests are in the experimental therapeutics of Non-Hodgkin’s & Hodgkin’s Lymphoma

Read More

Steven Devine, MD

As a member of the OSUCCC – James’ Leukemia Research Program, Steven Devine, MD, focuses his work on novel therapies involving the transplantation of adult blood-forming stem cells. His clinical research centers on allogeneic blood cell transplantation as a treatment for advanced acute.

Read More

Adrienne Dorrance, PhD

Adrienne Dorrance, PhD, is a member of the Leukemia Research Progam at the OSUCCC – James. Through a collaborative approach that crosses four colleges and 11 academic departments, her team examines all molecular aspects of tumor cells, integrating those features to improve leukemia risk.

Read More

Yvonne Efebera, MD

The development of osteolytic bone disease in Multiple Myeloma (MM) is the result of increased osteoclastic bone resorption and impairment of osteoblastic bone formation. The Wnt signaling pathway is important for osteoblastic differentiation.

Read More

Aharon Freud, MD, PhD

Dr. Freud's lab primarily studies the developmental biology of human natural killer (NK) cells that are evolutionarily designed to identify and destroy cancer. There is accumulating evidence that cancer cells target NK cell development as one means of immune evasion.

Read More

Patrick Green, PhD

The laboratory of Patrick Green is internationally recognized for their contributions to the understanding of the molecular basis of T-lymphocyte transformation and induction of leukemia/lymphoma and neurological disease by the human T-cell leukemia viruses (HTLVs). The Green lab has three areas.

Read More

Michael Grever, MD

Dr. Grever has over 30 years of experience in experimental chemotherapy and drug development for patients with chronic lymphocytic leukemia (CLL) and other hematologic malignancies. He performed the initial phase I studies on purine nucleoside analogs in patients with hematologic malignancies and.

Read More

H Grimes, PhD

Dr. Grimes was part of a team that first discovered the Growth factor independent-1 transcription factor which controls blood development and cancer, and he has shown that this factor is mutant in children with severe congenital neutropenia (SCN). Children with SCN lack neutrophils, blood.

Read More

Christina Guttke, PhD

Christina Diane Drenberg Guttke, PhD, is a member of the Leukemia Research Program at OSUCCC – James, where her research focuses on identifying therapeutic strategies to improve the long-term outcome for pediatric acute myeloid leukemia patients. In particular, she integrates genomic and.

Read More

Nyla Heerema, PhD

My research centers on chromosomal abnormalities in hematological malignancies. I am particularly involved in research of  chromosome changes in  pediatric acute lymphoblastic leukemia (ALL )  and their clinical significance,  including the use of fluorescence in situ hybridization (FISH)  for.

Read More

Erin Hertlein, PhD

Dr. Hertlein has been extensively involved in NF-?B and other cancer relevant cell signaling pathways throughout my career. Her work has focused on the mechanism of several therapeutic agents in chronic lymphocytic leukemia (CLL).

Read More

Craig Hofmeister, MD

Our research focuses primarily on phase I/II drug development in Multiple Myeloma with a focus on novel drugs. Initial research into the immunodeficiencies of myeloma and its connection with quality of life are just beginning.

Read More

Gang Huang, PhD

Research in Dr. Huang’s laboratory focuses on genetic and epigenetic regulations of blood cell normal development and leukemia. We first demonstrated that AML1/CBFß (a hetero-dimer transcription factor) and Mixed-Lineage Leukemia (MLL) protein (an enzyme which methylates lysine 4 of histone H3.

Read More

Samantha Jaglowski, MD

Dr. Jaglowski's clinical interests are Chronic Lymphocytic Leukemia (CLL) and indolent lymphoma, lymphoma, blood & marrow transplantation. Her research interests include pre- and post-transplant immunomodulatory therapies, late effects, & long-term transplant outcomes.

Read More

Rosa Lapalombella, PhD

Dr. Lapalombella's research interest focuses on two major areas: 1) Epigenetic alterations of cancer cells and 2) Development of experimental therapeutics for hematological disease.

Read More

L. James Lee, PhD

Dr. Lee's research interests are in polymer engineering of nanomaterials and nanotechnology with applications to Bio-Micro-Electro-Mechanical Systems (BioMEMS). MEMS emerged from IC manufacturing and is gaining applications in biomedical and optical communications fields.

Read More

Robert J Lee, PhD

Dr. Lee's lab is focused on targeted drug delivery systems based on nanoparticles. Nanoparticles can serve as carriers of therapeutic agents, including nucleic acids such as siRNA, miRNA and anti-miRs, and facilitate their therapeutic delivery.

Read More

Gerard Lozanski, MD

Dr. Lozanski is the Director of Hematopathology and the Director of the Clinical Flow Cytometry Laboratory at OSUMC. He is board certified in Anatomic and Clinical Pathology and Hematopathology.

Read More

David Lucas, PhD

Dr. Lucas' research interests include Pharmacology of novel anti-leukemic agents, role of transcriptional and translational regulation in tumor cell survival and drug resistance

Read More

James Mulloy, PhD

Research in the Mulloy Laboratory focuses on using human hematopoietic stem/progenitor cells (HSPC) to model leukemia. The prevailing theory is that acute myeloid leukemia is a stem cell disease.

Read More

Bethany Mundy-Bosse, PhD

My research is focused on defining the mechanisms driving innate immune cell defects in cancer patients, primarily hematologic malignancies.

Read More

Natarajan Muthusamy, DVM, PhD

Dr. Muthusamy's research interests are focused on the following areas: 1) Biological therapies for hematological malignancies with primary focus on acute and chronic leukemia; 2) Development and characterization of clinically relevant animal models of lymphoid malignancies; 3) Targeted delivery of

Read More

Stefan Niewiesk, DVM, PhD

One of the interests of the Niewiesk laboratory is the use of measles vaccine virus as oncolytic therapy to cure T cell leukemias. We use the mouse model of adult T cell leukemia to study the interaction between tumor cells, microenviroment and virus.

Read More

Christopher Oakes, PhD

Dr. Oakes’ current research focuses on investigating the role of epigenetics in hematological malignancies, with a primary focus on understanding the evolution and impact of epigenetic programming on the cancer cell phenotype. As the mechanisms that promote changes to the tumor epigenome are.

Read More

Qishen Pang, PhD

Dr. Pang's lab studies how Fanconi anemia (FA) proteins function to prevent stress-induced apoptosis and clonal evolution of hematopoietic stem cells and progenitors. Dr. Pang aslo works on a project involving the mechanism by which nucleophosmin (NPM) promotes cell proliferation and suppresses.

Read More

John Perentesis, MD, FAAP

Dr. Perentesis' clinical research focuses on the development of molecularly targeted therapies for pediatric and adolescent cancer. His laboratory program focuses on complementary studies of leukemia biology and pharmacogenetics of childhood cancer therapy.

Read More

A Mitchell Phelps, PhD

Dr. Phelps' expertise is in analytical methodologies and data modeling to study the disposition of novel anti-cancer agents. His lab is involved in both pre-clinical and clinical development of numerous small molecule anti-cancer and immuno-modulatory agents under development here at OSU.

Read More

Parvathi Ranganathan, PhD

Dr. Ranganathan, PhD is a member of the Leukemia Research Program at the OSUCCC-James. Dr. Ranganathan's primary research interest is to study the immunobiology of acute Graft-Versus-Host Disease (aGVHD) with the goal of developing selective immune suppression strategies that abrogate aGVHD.

Read More

Deepa Sampath, MD

Deepa Sampath, MD, is a member of the Leukemia Research Program at OSUCCC – James, where her research focuses on the epigenetics of lymphoid malignancies. One of her recent studies indicates a novel pharmacologic strategy that compromises the ability of acute myelogenous leukemia cells to.

Read More

Daniel Starczynowski, PhD

Dr. Starczynowski's laboratory focuses on the molecular, cellular, and genetic basis of hematologic malignancies, with a specific focus on Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). They have uncovered aberrant activation of the innate immune pathway in MDS, and now find.

Read More

Lara Sucheston-Campbell, PhD

I am a member of the Leukemia Research Program. As a genetic epidemiologist my research is focused on identifying, quantifying and characterizing relationships between exposures and genomic variation that modify susceptibility to complex cancer phenotypes.

Read More

Susheela Tridandapani, PhD

Dr. Tridandapani's research examines the molecular mechanisms of innate immune responses to bacterial pathogens and IgG-immune complexes, particularly in the context of monoclonal antibody therapy for cancer.

Read More

Sumithira Vasu, MD

Dr. Vasu's clinical interests include acute myeloid leukemia, Allogeneic hematopoietic stem cell transplantation. Her research interests include pPharmacologic and Immunologic therapies in Allogeneic transplantation to pre-emptively manage relapse and GvHD.

Read More

Alison Walker, MD

Dr. Walker's research interests are in AML and MDS(Acute Myeloid Leukemia and Myelodysplastic Syndromes)

Read More

Basem William, MD

Basem William, MD, MRCP(UK), FACP, is a clinical investigator with focus on translational approaches to the treatment of lymphomas. His background in lymphoma and clinical investigation comes from fellowship training at the University of Nebraska; an international center of excellence for.

Read More

Jennifer Woyach, MD

Dr. Woyach’s research interests include chronic lymphocytic leukemia and other hematologic malignancies. Her laboratory research focuses on the role of Bruton’s Tyrosine Kinase (BTK) in the development and expansion of CLL as well as therapeutic BTK inhibition in CLL using murine and cellular.

Read More

Pearlly Yan, PhD

Dr. Yan's research uses sequencing approach to interrogate cancer and disease-related methylomes, developing novel sequencing library protocols and custom computation pipeline to capture the methylome at high resolution.

Read More

Yi Zheng, PhD

Yi Zheng, PhD, is a member of the Leukemia Research Program at OSUCCC – James and is based in the Pediatrics Department at the University of Cincinnati’s College of Medicine. His research focuses on physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis.

Read More

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Find a Scientific Publication

Search for Clinical Trials